Guanfacine Dosage: Why Prescribers Raise It 1 mg at a Time

Guanfacine is one of the few ADHD medications where the pace of reaching your dose matters almost as much as the dose itself. Go too fast, and the first thing many people notice is exhaustion, dizziness, or a heavy fog, not better focus.

Guanfacine works by activating alpha-2A receptors, and the same action that helps the brain regulate attention also lowers blood pressure and heart rate. The Intuniv prescribing information describes both sides of that coin: in monotherapy trials, symptom improvement rose with dose and exposure, and so did low blood pressure, slow heart rate, and sedation. A dosing schedule has to handle both with precision.

The standard approach does that well. Guanfacine extended-release is FDA-approved for ADHD in children and adolescents, and a 2023 guanfacine meta-analysis of 12 randomized trials with 2,653 participants found that 58.5% of people on guanfacine responded in studies shorter than 10 weeks, versus 29.4% on placebo. The medication works, and the evidence for it is consistent.

But a weekly step only works if someone is paying attention to what each step does, and at Siggy we believe dose changes deserve that kind of attention rather than a check-in months later. Understanding why the schedule moves 1 mg at a time, what your target might be, and how to come off safely makes the first month far less confusing. The slow pace follows the drug’s own dose-response biology, not guesswork.

What This Page Covers

• The Standard Guanfacine ER Schedule
• Why Prescribers Go 1 mg at a Time
• Finding Your Target Dose
• Guanfacine Dosing in Adults
• Extended-Release vs Immediate-Release
• Interactions, Missed Doses, and Tapering
• How Siggy Thinks About Dose Changes

The Standard Guanfacine ER Schedule

The label’s instructions are simple. Start at 1 mg once a day, taken in the morning or evening at about the same time each day, and adjust by no more than 1 mg per week. The target range is 0.05 to 0.12 mg per kilogram of body weight a day, which works out to a total of 1 to 7 mg.

A few practical rules come with it. Swallow the tablet whole, since crushing, chewing, or breaking it speeds up how fast the drug is released. Avoid taking it with a high-fat meal, which increases how much of the drug your body absorbs.

In practice, that often looks like 1 mg in week one, 2 mg in week two, 3 mg in week three, and so on, pausing whenever symptoms are well controlled or side effects become limiting. Your prescriber may hold at a dose for longer than a week, and that’s normal.

Why Prescribers Go 1 mg at a Time

The main reason is that guanfacine’s side effects follow the dose. The label lists low blood pressure, slow heart rate, and sedative events among the dose- and exposure-related risks seen in trials, and it advises titrating slowly in people with a history of low blood pressure, heart block, slow heart rate, fainting, or heart disease.

Sleepiness also has a predictable rhythm. A pooled analysis of four pediatric trials found that sedative side effects generally peaked in the first week a target dose was reached and then declined. The same analysis found that symptom improvement held up even in people who never had sedation, which suggests the benefit isn’t simply drowsiness.

European prescribing guidance adds a monitoring rhythm. The European product information for Intuniv recommends checking heart rate and blood pressure weekly during titration and notes that sedation typically lasts two to three weeks, sometimes longer. One step per week gives each increase time to settle before the next one lands on top of it.

Finding Your Target Dose

For children and teens, the label’s dosing table ties target doses to body weight.

Body Weight	Typical Target Range per Day
25 to 33.9 kg	2 to 3 mg
34 to 41.4 kg	2 to 4 mg
41.5 to 49.4 kg	3 to 5 mg
49.5 to 58.4 kg	3 to 6 mg
58.5 to 91 kg	4 to 7 mg
Over 91 kg	5 to 7 mg

Those ranges come from the label, with one important limit: doses above 4 mg a day haven’t been evaluated in children ages 6 to 12 or in trials combining guanfacine with stimulants, and doses above 7 mg a day haven’t been evaluated in adolescents. The label reports clinically relevant improvement starting around 0.05 to 0.08 mg/kg, with doses up to 0.12 mg/kg adding benefit if tolerated.

Response takes some patience. In the 2023 meta-analysis, response rates in studies longer than 10 weeks were 63.6% on guanfacine versus 39.7% on placebo, so a fair trial usually means giving each dose enough time to show what it can do.

Guanfacine Dosing in Adults

In the U.S., guanfacine ER is approved for ADHD in children and adolescents, so adult use is off-label, and the label notes that safety and effectiveness haven’t been established in older adults.

Much of the adult trial data comes from Japan, where guanfacine ER has been studied in adults. In a randomized placebo-controlled trial of 201 adults, guanfacine ER was titrated from 2 mg to 4 to 6 mg a day over five weeks and improved ADHD symptoms more than placebo. It also had a cost: 19.8% of people on guanfacine stopped because of side effects, versus 3.0% on placebo, and the most common side effects included sleepiness, thirst, lower blood pressure, and dizziness on standing.

A follow-up subgroup analysis of the same trial found that side effects leading to discontinuation were about three times more common in women than in men. Every participant weighing under 50 kg had at least one side effect during dose optimization. Those findings are a strong argument for adult titration that’s slow and closely watched.

Extended-Release vs Immediate-Release

Guanfacine comes in two very different forms. Immediate-release guanfacine, sold as Tenex, has a long history as a blood pressure medication, while Intuniv is the extended-release version approved for ADHD.

They aren’t interchangeable. The label says not to substitute one for the other milligram for milligram, because extended-release guanfacine has a 60% lower peak level, 43% lower bioavailability, and a peak about 3 hours later than the same dose of immediate-release. If you’re switching from immediate-release, the label calls for stopping it and titrating the extended-release version from the standard schedule.

Interactions, Missed Doses, and Tapering

Guanfacine is broken down mainly by a liver enzyme called CYP3A4, so some medications change how much of it stays in your system:

• Strong and moderate CYP3A4 inhibitors, such as ketoconazole, raise guanfacine levels, and the label calls for cutting the target dose to 50%.
• Strong and moderate CYP3A4 inducers, such as carbamazepine, lower guanfacine levels, and the label allows titrating up to double the target dose over one to two weeks.

After two or more missed doses in a row, the label advises prescribers to consider re-titrating based on how well you tolerate it, rather than jumping straight back to the full dose.

Stopping matters as much as starting. The label warns that blood pressure and heart rate can rise after guanfacine is stopped, and it calls for tapering by no more than 1 mg every 3 to 7 days while monitoring both. If you have a severe headache, chest pain, fainting, or a very fast or pounding heartbeat, call 911 or seek emergency care. Our guide to guanfacine’s sedation timeline covers what to expect week by week.

How Siggy Thinks About Dose Changes

“No one checks in to see if it’s actually working.” With a medication titrated weekly, that gap can mean several dose changes pass without anyone seeing how each one landed.

Guanfacine and ADHD care sit outside the SSRI-based anxiety and depression care that Siggy’s clinical model focuses on today, so Siggy doesn’t prescribe or manage guanfacine. What carries over is the principle behind a slow titration: every dose change is a small experiment, and it works best when side effects and symptom changes reach a licensed prescriber quickly instead of waiting for the next scheduled visit.

Guanfacine’s weekly pace is how the medication’s benefits get time to build while its sedation and blood pressure effects stay manageable, and that’s a clinical reason rather than a formality. For more on who guanfacine tends to help and how it fits alongside stimulants, see our guide to guanfacine for ADHD, sleep, and focus. If you’re also dealing with anxiety or depression and want that kind of close follow-through built into your care, Siggy can help.

Ready to take control of your mental health? Start your anonymous intake with Siggy and get your plan reviewed by a licensed prescriber.

This article is for education only and isn’t a substitute for personal medical advice. Talk with your own clinician before starting, changing, or stopping any medication.